Comparative effectiveness research: the view from the NHLBI.
作者信息
Lauer Michael S
机构信息
Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, USA.
出版信息
J Am Coll Cardiol. 2009 Mar 24;53(12):1084-6. doi: 10.1016/j.jacc.2008.11.047.
Abstract
摘要
相似文献
1
Comparative effectiveness research: the view from the NHLBI.
J Am Coll Cardiol. 2009 Mar 24;53(12):1084-6. doi: 10.1016/j.jacc.2008.11.047.
2
Can physicians practice cost-effective medicine?
Clin Cardiol. 1998 Jan;21(1):2-3. doi: 10.1002/clc.4960210101.
3
Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute.
Circulation. 2013 Oct 8;128(15):1713-5. doi: 10.1161/CIRCULATIONAHA.113.004587. Epub 2013 Jun 19.
4
Implementing the National Heart, Lung, and Blood Institute's Strategic Vision in the Division of Cardiovascular Sciences.
Circ Res. 2019 Feb 15;124(4):491-497. doi: 10.1161/CIRCRESAHA.118.314338.
5
Two Perspectives of the Appropriate Use Criteria in Cardiology Practice: Advantageous and Useful or Limiting and Harmful?
Rev Cardiovasc Med. 2017;18(2):73-77. doi: 10.3909/ricm0884.
6
Cardiology and the quality of medical practice. The Cardiology Working Group.
JAMA. 1991;265(4):482-5; discussion 496-8. doi: 10.1001/jama.1991.03460040072032.
7
Measuring cost effectiveness of cardiac care.
J Cardiovasc Manag. 1999 Jan-Feb;10(1):24-30.
8
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
Circulation. 2014 Sep 30;130(14):1192-203. doi: 10.1161/CIRCULATIONAHA.113.008428.
9
Advancing recognition of the responsibilities of cardiac sonographers.
J Am Soc Echocardiogr. 2009 Dec;22(12):1414-6. doi: 10.1016/j.echo.2009.10.003.
10
Practice expense: applying accounting principles in a specialty practice.
Pacing Clin Electrophysiol. 1997 Nov;20(11):2853-4. doi: 10.1111/j.1540-8159.1997.tb05443.x.
引用本文的文献
1
Exploration of Factors Associated With Surgeon Deviation From Practice Guidelines for Management of Inguinal Hernias.
JAMA Netw Open. 2020 Nov 2;3(11):e2023684. doi: 10.1001/jamanetworkopen.2020.23684.
2
Exploration of Surgeon Motivations in Management of Abdominal Wall Hernias: A Qualitative Study.
JAMA Netw Open. 2020 Sep 1;3(9):e2015916. doi: 10.1001/jamanetworkopen.2020.15916.
3
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
J Gen Intern Med. 2014 Nov;29(11):1475-83. doi: 10.1007/s11606-014-2947-1.
4
Comparative effectiveness research.
AJNR Am J Neuroradiol. 2014 Sep;35(9):1677-80. doi: 10.3174/ajnr.A3985. Epub 2014 May 29.
5
Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes.
Am Heart J. 2012 Aug;164(2):207-14. doi: 10.1016/j.ahj.2012.05.016.
6
Full report from the first annual Heart Rhythm Society Research Forum: a vision for our research future, "dream, discover, develop, deliver".
Heart Rhythm. 2011 Dec;8(12):e1-12. doi: 10.1016/j.hrthm.2011.10.024. Epub 2011 Nov 7.
7
Comparative effectiveness regulations and pharmaceutical innovation.
Pharmacoeconomics. 2010;28(10):877-87. doi: 10.2165/11537570-000000000-00000.
8
What have we learned about trial design from NIMH-funded pragmatic trials?
Neuropsychopharmacology. 2010 Dec;35(13):2491-501. doi: 10.1038/npp.2010.115. Epub 2010 Aug 25.
9
Cardiovascular disease surveillance in the comparative effectiveness landscape.
Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):404-6. doi: 10.1161/CIRCOUTCOMES.109.901249.
本文引用的文献
1
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.
Epidemiology. 2008 Nov;19(6):766-79. doi: 10.1097/EDE.0b013e3181875e61.
2
Defining optimal research study design for cardiovascular imaging using computed tomography angiography as a model.
Am J Cardiol. 2008 Oct 1;102(7):943-8. doi: 10.1016/j.amjcard.2008.05.037. Epub 2008 Jul 17.
3
Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.
4
Information on cost-effectiveness: an essential product of a national comparative effectiveness program.
Ann Intern Med. 2008 Jun 17;148(12):956-61. doi: 10.7326/0003-4819-148-12-200806170-00222. Epub 2008 May 15.
5
Cost-effectiveness information: yes, it's important, but keep it separate, please!
Ann Intern Med. 2008 Jun 17;148(12):967-8. doi: 10.7326/0003-4819-148-12-200806170-00224. Epub 2008 May 15.
6
What cannot be said on television about health care.
JAMA. 2007 May 16;297(19):2131-3. doi: 10.1001/jama.297.19.2131.
7
Coronary intervention for persistent occlusion after myocardial infarction.
N Engl J Med. 2006 Dec 7;355(23):2395-407. doi: 10.1056/NEJMoa066139. Epub 2006 Nov 14.
8
Is technological change in medicine always worth it? The case of acute myocardial infarction.
Health Aff (Millwood). 2006 Mar-Apr;25(2):w34-47. doi: 10.1377/hlthaff.25.w34. Epub 2006 Feb 7.
9
Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction.
JAMA. 2005 Mar 16;293(11):1329-37. doi: 10.1001/jama.293.11.1329.
10
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
Zotero 插件